Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC11A2 | P49281 | 1/20 | 0.45 |
| ▸ | PGK1 | P00558 | 1/20 | 0.44 |
| ▸ | PGK2 | P07205 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | AOC1 | P19801 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392356 | 0.89 | SLC11A2 (0.38) | SLC11A2PGK1PGK2HTR1DCYP3A4 | |
| SCHEMBL2371105 | 0.83 | CA1 (0.39) | SLC11A2PGK1PGK2HTR1DCYP3A4 | |
| SCHEMBL6589242 | 0.82 | SLC11A2 (0.35) | SLC11A2PGK1PGK2HTR1D | |
| SCHEMBL395734 | 0.82 | SLC11A2 (0.35) | SLC11A2PGK1PGK2HTR1DCYP3A4 | |
| SCHEMBL28017661 | 0.79 | SLC11A2 (0.35) | SLC11A2PGK1PGK2HTR1DCYP3A4 | |
| SCHEMBL27430698 | 0.79 | HTR1D (0.44) | SLC11A2PGK1PGK2HTR1DHTR1B | |
| SCHEMBL14135238 | 0.77 | AOC3 (0.35) | AOC3AOC1 | |
| SCHEMBL111999 | 0.77 | HRH3 (0.40) | HTR1DTSHRHTR1BTAAR1 | |
| SCHEMBL395903 | 0.74 | POLB (0.35) | TSHRAOC3HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL7894748 | 0.74 | LMNA (0.42) | HTR1DTSHRAOC3HTR1BTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200241008-A1 | MONITORING INFLAMMATION STATUS | MOLOGIC LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| EP-3111226-B1 | MONITORING INFLAMMATION STATUS | MOLOGIC LTD (GB) | 2019-05-01 | — | — | EP | disclosed |
| US-20170108511-A1 | Monitoring Inflammation Status | MOLOGIC LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20100240713-A1 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-23 | — | — | US | disclosed |
| US-20100240713-A1 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-23 | — | — | US | disclosed |
| US-20100240713-A1 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-23 | — | — | US | disclosed |
| EP-2068855-A2 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008151288-A2 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008151288-A2 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240713-A1 | AROMATIC AND HETEROAROMATIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | SLC40A1, PAH, FECH | SLC11A2 175/4885PGK1 1732/4885PGK2 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.